Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genz-112638 once-daily vs twice-daily in type 1 Gaucher disease
CTR20140075Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eliglustat in Gaucher disease type 1 (GD1), sponsored by Sanofi. Started May 2014; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on CTR20140075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140075.